Chan Yee Kwan, Brar Manreetpal Singh, Kirjavainen Pirkka V, Chen Yan, Peng Jiao, Li Daxu, Leung Frederick Chi-Ching, El-Nezami Hani
5S12, Kadoorie Biological Sciences Building, School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong.
5N01, Kadoorie Biological Sciences Building, School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong.
BMC Microbiol. 2016 Nov 8;16(1):264. doi: 10.1186/s12866-016-0883-4.
Atherosclerosis appears to have multifactorial causes - microbial component like lipopolysaccharides (LPS) and other pathogen associated molecular patterns may be plausible factors. The gut microbiota is an ample source of such stimulants, and its dependent metabolites and altered gut metagenome has been an established link to atherosclerosis. In this exploratory pilot study, we aimed to elucidate whether microbial intervention with probiotics L. rhamnosus GG (LGG) or pharmaceuticals telmisartan (TLM) could improve atherosclerosis in a gut microbiota associated manner.
Atherosclerotic phenotype was established by 12 weeks feeding of high fat (HF) diet as opposed to normal chow diet (ND) in apolipoprotein E knockout (ApoE) mice. LGG or TLM supplementation to HF diet was studied.
Both LGG and TLM significantly reduced atherosclerotic plaque size and improved various biomarkers including endotoxin to different extents. Colonial microbiota analysis revealed that TLM restored HF diet induced increase in Firmicutes/Bacteroidetes ratio and decrease in alpha diversity; and led to a more distinct microbial clustering closer to ND in PCoA plot. Eubacteria, Anaeroplasma, Roseburia, Oscillospira and Dehalobacteria appeared to be protective against atherosclerosis and showed significant negative correlation with atherosclerotic plaque size and plasma adipocyte - fatty acid binding protein (A-FABP) and cholesterol.
LGG and TLM improved atherosclerosis with TLM having a more distinct alteration in the colonic gut microbiota. Altered bacteria genera and reduced alpha diversity had significant correlations to atherosclerotic plaque size, plasma A-FABP and cholesterol. Future studies on such bacterial functional influence in lipid metabolism will be warranted.
动脉粥样硬化似乎有多种病因——微生物成分如脂多糖(LPS)和其他病原体相关分子模式可能是合理的因素。肠道微生物群是此类刺激物的丰富来源,其相关代谢产物和肠道宏基因组改变已被确认为与动脉粥样硬化有关。在这项探索性初步研究中,我们旨在阐明用益生菌鼠李糖乳杆菌GG(LGG)或药物替米沙坦(TLM)进行微生物干预是否能以与肠道微生物群相关的方式改善动脉粥样硬化。
通过给载脂蛋白E基因敲除(ApoE)小鼠喂食12周高脂肪(HF)饮食而非正常饲料(ND)来建立动脉粥样硬化表型。研究了在HF饮食中补充LGG或TLM的情况。
LGG和TLM均显著减小了动脉粥样硬化斑块大小,并在不同程度上改善了包括内毒素在内的各种生物标志物。群落微生物分析显示,TLM恢复了HF饮食诱导的厚壁菌门/拟杆菌门比例增加和α多样性降低;并在主坐标分析(PCoA)图中导致更明显的微生物聚类,更接近ND组。真细菌、厌氧支原体、罗斯氏菌属、颤螺菌属和脱卤杆菌似乎对动脉粥样硬化有保护作用,并且与动脉粥样硬化斑块大小、血浆脂肪细胞脂肪酸结合蛋白(A-FABP)和胆固醇呈显著负相关。
LGG和TLM改善了动脉粥样硬化,其中TLM对结肠肠道微生物群的改变更为明显。细菌属的改变和α多样性的降低与动脉粥样硬化斑块大小、血浆A-FABP和胆固醇显著相关。未来有必要对这种细菌在脂质代谢中的功能影响进行研究。